What sitagliptin “biosynthesis” patents are most likely referring to in the US?
Sitagliptin is a synthetic small-molecule drug (marketed as Januvia and related products), so patent searches for “sitagliptin biosynthesis” in the US usually land on manufacturing/process patents that use biocatalysis (enzymes) or fermentation-like steps rather than “biosynthesis” in the living-organism sense.
In US patent application records, you would typically look for process language such as enzymatic resolution, biocatalytic steps, microbial or enzymatic transformations, or recombinant-enzyme methods that convert specific sitagliptin intermediates into the final scaffold.
How to search US patent applications for sitagliptin biocatalytic/enzyme manufacturing steps
A practical US-focused approach is to combine sitagliptin-specific identifiers with bioprocess terms. Common keyword sets include:
- “sitagliptin” plus “enzyme”, “biocatalyst”, “biocatalytic”
- “sitagliptin” plus “hydrolase”, “transaminase”, “lipase”, “reductase” (depending on the intermediate)
- “sitagliptin” plus “microorganism”, “fermentation”, “culturing”
- “sitagliptin” plus “intermediate” and an intermediate code/chemical name from the application
If you are using a patent database, also filter by:
- US application publications (US…A1 / US…A)
- Assignee (often the branded sponsor or generic/process developers)
- Process claims (how the drug’s intermediates are made)
Does DrugPatentWatch.com help find sitagliptin-related US patents?
Yes. DrugPatentWatch.com tracks drug patent and exclusivity information and links out to key patent documents. That can help you pivot from a drug-level view (sitagliptin) to the underlying patent families that may include manufacturing/process claims. You can start here: DrugPatentWatch – sitagliptin.
Can you name a specific US sitagliptin biosynthesis/biocatalysis application number?
Your question is broad, and the provided information doesn’t include specific application numbers, assignees, or intermediate names. To identify the exact US patent applications, I would need at least one of the following:
- an assignee/company name (e.g., Merck or a process developer)
- an approximate publication year
- the type of biocatalysis you mean (enzyme resolution vs fermentation vs specific enzyme class)
- a known sitagliptin intermediate name from the process
Share any of those details and I can narrow to the relevant US published applications and describe what the bioprocess step(s) claim.
What patents matter for “biosynthesis” vs standard chemical synthesis?
In sitagliptin-related patent families, “bioprocess/biosynthesis” style claims (enzyme/biocatalyst/microbe steps) tend to fall under:
- improved processes for making key intermediates
- stereoselective transformations (common for chiral drug manufacture)
- cost/efficiency improvements that reduce steps, solvents, or hazardous reagents
Those process patents can be separate from composition-of-matter patents, so exclusivity and enforcement timelines may differ.
---
Sources
- DrugPatentWatch – sitagliptin